895128-46-8

Basic information

• Product Name: 3-chloroisonicotinoyl chloride
• Synonyms: 3-chloroisonicotinoyl chloride
• CAS NO: 895128-46-8
• Molecular Weight: 176.002
• Mol File: 895128-46-8.mol
• Article Data: 16

Chemical Properties

• CAS DataBase Reference: 3-chloroisonicotinoyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 3-chloroisonicotinoyl chloride(895128-46-8)
• EPA Substance Registry System: 3-chloroisonicotinoyl chloride(895128-46-8)

Safety Data

• Hazardous Substances Data: 895128-46-8(Hazardous Substances Data)

Upstream product

• 88912-27-0 3-chloro-isonicotinic acid 

Downstream Products

• 929569-17-5 (3-chloropyridin-4-yl)(5-hydroxy-1-phenyl-1H-pyrazol-4-yl)methanone 
• 929569-16-4 (3-chloropyridin-4-yl)(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)methanone 
• 1463965-39-0 3-chloro-N-(2-(m-tolyloxy)ethyl)isonicotinamide 
• 929569-06-2 3-methyl-1-phenylpyrazolo[4',3':5,6]pyrano[3,2-c]pyridin-4(1H)-one 
• 929569-07-3 1-phenylpyrazolo[4',3':5,6]pyrano[3,2-c]pyridin-4(1H)-one 
• 929569-18-6 (3-chloropyridin-4-yl)-[5-hydroxy-1-(4-methoxybenzyl)-1H-pyrazol-4-yl]methanone 
• 929569-08-4 1-(4-methoxybenzyl)pyrazolo[4',3':5,6]pyrano[3,2-c]pyridin-4(1H)-one 
• 1429043-81-1 N-benzyl-3-chloro-N-(cyclopent-1-en-1-yl)isonicotinamide 
• 1035214-17-5 3-(3-chloro-4-isopropoxyphenyl)-5-(3-chloropyridin-4-yl)-[1,2,4]-oxadiazole 

Relevant articles and documents

Discovery of pyrazolo[1,5-a]pyrimidine-3-carbonitrile derivatives as a new class of histone lysine demethylase 4D (KDM4D) inhibitors

Herein we report the discovery of a series of new small molecule inhibitors of histone lysine demethylase 4D (KDM4D). Molecular docking was first performed to screen for new KDM4D inhibitors from various chemical databases. Two hit compounds were retrieved. Further structural optimization and structure-activity relationship (SAR) analysis were carried out to the more selective one, compound 2, which led to the discovery of several new KDM4D inhibitors. Among them, compound 10r is the most potent one with an IC50 value of 0.41?±?0.03?μM against KDM4D. Overall, compound 10r could be taken as a good lead compound for further studies.

AMIDO-SUBSTITUTED AZOLE COMPOUNDS

The present invention relates to amido-substituted azole compounds of general formula (I), in which X1, X2, R1, R2, R4, R5, R7 and R8 are as defined in the claims which are inhibitors of TNKS1 and/or TNKS2, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.

Novel TypeII Fatty Acid Biosynthesis (FAS II) Inhibitors as Multistage Antimalarial Agents

Malaria is a potentially fatal disease caused by Plasmodium parasites and poses a major medical risk in large parts of the world. The development of new, affordable antimalarial drugs is of vital importance as there are increasing reports of resistance to the currently available therapeutics. In addition, most of the current drugs used for chemoprophylaxis merely act on parasites already replicating in the blood. At this point, a patient might already be suffering from the symptoms associated with the disease and could additionally be infectious to an Anopheles mosquito. These insects act as a vector, subsequently spreading the disease to other humans. In order to cure not only malaria but prevent transmission as well, a drug must target both the blood- and pre-erythrocytic liver stages of the parasite. P.falciparum (Pf) enoyl acyl carrier protein (ACP) reductase (ENR) is a key enzyme of plasmodial typeII fatty acid biosynthesis (FASII). It has been shown to be essential for liver-stage development of Plasmodium berghei and is therefore qualified as a target for true causal chemoprophylaxis. Using virtual screening based on two crystal structures of PfENR, we identified a structurally novel class of FAS inhibitors. Subsequent chemical optimization yielded two compounds that are effective against multiple stages of the malaria parasite. These two most promising derivatives were found to inhibit blood-stage parasite growth with IC50 values of 1.7 and 3.0μM and lead to a more prominent developmental attenuation of liver-stage parasites than the gold-standard drug, primaquine.